Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic role of gene mutations in chronic myelomonocytic leukemia (CMML) patients treated with hypomethylating agents: A report on 183 patients
    Meeting Abstract

    Duchmann, M.; Yalniz, F.; Sanna, A.; Sallman, D. A.; Coombs, C. C.; Renneville, A.; Kosmider, O.; Braun, T.; Platzbecker, U.; Willems, L.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Single-arm phase II trial of pegylated interferon alpha 2a in patients with high-risk essential thrombocythemia or polycythemia vera resistant or intolerant to hydroxyurea: MPN symptom impact & quality of life results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) protocol 111 global phase II trial
    Meeting Abstract

    Dueck, A. C.; Mascarenhas, J.; Kosiorek, H. E.; Yacoub, A.; Prchal, J. T.; Berenzon, D.; Baer, M. R.; Ritchie, E. K.; Silver, R. T.; Kessler, C. M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A phase I study of FLX925, a dual FLT3 and CDK4/6 inhibitor in patients with relapsed or refractory acute myeloid leukemia (AML)
    Meeting Abstract

    Daver, N.; Pollyea, D. A.; Rizzieri, D. A.; Palmer, J.; Rampal, R. K.; Dinner, S.; Bixby, D. L.; Percival, M. E. M.; Kovacsovics, T.; Begna, K. H.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Phase 2 trial of single-agent cobimetinib for adults with BRAF V600-mutant and wild-type histiocytic disorders
    Meeting Abstract

    Diamond, E. L.; Durham, B. H.; Dogan, A.; Hyman, D. M.; Rampal, R. K.; Ulaner, G.; Brody, L.; Abdel-Wahab, O.
    Blood (2017)

    Fulltext@MSK | Save
  • Risk of hyponatremia and associated clinical characteristics in patients with acute lymphoblastic leukemia after CD19 targeted chimeric antigen receptor (CAR) T-cells
    Meeting Abstract

    Dixon, B. N.; Daley, R. J.; Horvat, T. Z.; Buie, L. W.; Hsu, M.; Latcha, S.; Brentjens, R. J.; Park, J. H.
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients with acute myeloid leukemia (AML) treated within the international ratify study
    Meeting Abstract

    Döhner, K.; Thiede, C.; Larson, R. A.; Prior, T. W.; Marcucci, G.; Jones, D.; Krauter, J.; Heuser, M.; Lo Coco, F.; Ottone, T.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: Results from part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML)
    Meeting Abstract

    Dawson, M.; Stein, E. M.; Huntly, B. J. P.; Karadimitris, A.; Kamdar, M.; de Larrea, C. F.; Dickinson, M. J.; Yeh, P. S. H.; Daver, N.; Chaidos, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Long-term cardiac, vascular and hypertensive safety of bosutinib in patients with Philadelphia chromosome-positive (Ph+) leukemia resistant or intolerant to prior therapy
    Meeting Abstract

    Cortes, J. E.; Kim, D. W.; Kantarjian, H. M.; Mauro, M. J.; Aguiar, J. M.; An, F.; Leip, E.; Gambacorti-Passerini, C.; Brummendorf, T. H.
    Blood (2017)

    Fulltext@MSK | Save
  • LSD1 inhibition exerts its anti-leukemic effect by recommissioning PU.1-and C/Ebpα-dependent enhancers in AML
    Meeting Abstract

    Cusan, M.; Cai, S.; Mohammad, H. P.; Krivtsov, A. V.; Chramiec, A.; Loizou, E.; Tenen, D. G.; Ye, M.; Will, B.; Steidl, U. G.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • High dose cyclophosphamide and pre-treatment disease burden dictate response and survival in a multicenter clinical trial using CD19-specific CAR T cells for relapsed/refractory B-ALL
    Meeting Abstract

    Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Park, J. H.; Sauter, C. S.; Smith, E. L.; Boulad, F.; Cancio, M. I.; Forlenza, C.; more...
    Blood (2017)

    Fulltext@MSK | Save